Physician profile
Amy M Lacouture
NPI 1841617594
$662,789.54
in general payments reported to CMS, 2019-2025
7 companies · $164K in 2025
The $164K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96K · 2022: $133K · 2023: $139K · 2024: $132K · 2025: $164K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $263K · Travel and Lodging: $88K · Consulting Fee: $70K · Food and Beverage: $12K · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $263,185.50 |
| Travel and Lodging | $88,427.37 |
| Consulting Fee | $70,053.50 |
| Food and Beverage | $12,214.56 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $634,714.22 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $26,886.26 | 2021-2023 | Aristada, Aristada Initio, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $1,003.23 | 2024 | Cobenfy |
| Axsome Therapeutics, INC. | $138.60 | 2024 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.68 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $17.23 | 2024 | Uzedy |
| Janssen Pharmaceuticals, INC | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Lacouture listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.